RT Journal Article
SR Electronic
T1 7 Quantifying the bio-distribution of transplanted HESC-ECS in a murine model of HLI by QPCR
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP A3
OP A4
DO 10.1136/heartjnl-2017-311433.7
VO 103
IS Suppl 2
A1 Lucija Fleisinger
A1 Mark G MacAskill
A1 Joanne C Mountford
A1 Andrew H Baker
A1 David E Newby
A1 Patrick WF Hadoke
YR 2017
UL http://heart.bmj.com/content/103/Suppl_2/A3.2.abstract
AB Introduction Beneficial effects of stem/progenitor cell therapies for the treatment of ischaemic diseases have been established; however, there remains conflicting evidence on whether cells act by incorporation into the existing vasculature or by paracrine effects.Objective This study aims to quantify the bio-distribution of transplanted, proangiogenic, human embryonic stem cell-derived endothelial cells (hESC-ECs) in a murine model of hind limb ischaemia over 21 days using qPCR-detection of human DNA.Methods CD1 nude mice (male, 6–8 weeks old; n=6 per group) underwent femoral artery ligation followed by injection with hESC-ECs into ischaemic muscle of the hindlimb. Mice were sacrificed at 0 hour, 4 hour, 24 hour, 7d, 14d, and 21d post-transplantation, and DNA extracted from the hind limb. A paired-qPCR assay was run with a set of human-specific and mouse-specific primers to allow for detection of hESC-ECs in mouse tissue.Results A standard curve was constructed using mixtures of DNA extracted from mouse tissue and a population of hESC-ECs. The mean percentage of human cells at each time-point was determined accordingly. At the first time-point (0 hour), 1.77%±0.55% human cells were present within the ischaemic limb, with no significant change at 4 hour post-injection. However, by 24 hour and 7 days post-injection, the% human cells present significantly decreased to 0.67%±0.24% (p=0.05) and 0.35%±0.09% (p=0.05) respectively. At 14 and 21 days post-injection, the level of human DNA present had decreased to background levels.Conclusion Our results suggest the majority of injected hESC-EC cleared from the injection site within the first 24 hours, with the remainder of the cells no longer present at 14 days post-injection. This is consistent with imaging data obtained prior to this study, and suggests that injected hESC-ECs improve perfusion in the mouse ischaemic limb by a paracrine mechanism rather than direct incorporation into the existing vasculature.